Holen Sie sich die Stockscreener-App
22.53
2.22%
0.49
Handel nachbörslich:
22.60
0.07
+0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - The Motley Fool
Jim Cramer Warns on Pfizer (PFE): “That 7.7% Yield Is Not a Sign of Strength – It’s a Sign of Weakness” - Yahoo Finance
Cantor Fitzgerald Initiates a Hold Rating on Pfizer (PFE) - The Globe and Mail
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Pfizer Inc. (PFE): Among Recent Activist Investor Campaigns - Yahoo Finance
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
Pfizer Inc. (NYSE: PFE) Stock: Can New Drug Pipeline Rescue Tumbling Share Price? - CoinCentral
Prostate Health Market Top Companies StudyPfizer Inc., Lily, Bayer AG, Abbolt, GSK plc., Merck KGaA, ProArc. - openPR.com
Bernstein Sticks to Their Hold Rating for Pfizer (PFE) - The Globe and Mail
TD Cowen Adjusts Price Target on Pfizer to $28 From $32, Maintains Hold Rating - marketscreener.com
Cancer Drugs Market Overall Study Report 2025-2032 | Pfizer - openPR.com
US CDC ACIP Puts GSK’s Penmenvy Even With Pfizer, Prepares For Infant MedQuadFi, Lyme Vaccines - insights.citeline.com
Lobbying Update: $4,240,000 of PFIZER INC. lobbying was just disclosed - Nasdaq
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025) - 24/7 Wall St.
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline - Benzinga
Wolfe Research Adjusts Pfizer Price Target to $22 From $25, Keeps Underperform Rating - marketscreener.com
3 High Yielding Dividend Stocks Near 52-Week Lows - 24/7 Wall St.
BofA Securities Adjusts Price Target on Pfizer to $26 From $29, Maintains Neutral Rating - marketscreener.com
Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5% - Insider Monkey
How a scrapped Pfizer drug became a winner for SpringWorks - PharmaVoice
Pfizer: Is The 7.63% Dividend Yield Worth The Effort? (NYSE:PFE) - Seeking Alpha
Dermatomyositis Drug Market Deep Research 2025-2032 | Pfizer - openPR.com
Heparin Calcium Market Detailed In New Research Report 2025 | - openPR.com
How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock - Benzinga
Pfizer (PFE) Faces Activist Pressure from Starboard Value - GuruFocus
Pfizer Inc. (PFE): Among Jeff Smith’s Top Activist Targets - Insider Monkey
Trump’s executive order on drug pricing; Pfizer drops oral obesity drug; Seed rounds at their lowest in years; and more - Endpoints News
Pfizer Inc. - Britannica
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
ACE Inhibitor Market Set to Witness Significant Growth by 2025-2032 | Pfizer Inc.,Merck & Co., Inc.,Novartis AG - openPR.com
Xylose Absorption Test Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Bristol-Myers Squibb Company - openPR.com
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock? - Yahoo Finance
Lilly Soars As Study Shows Weight-Loss Pill to Pass Ozempic - Yahoo Finance
Pfizer (PFE) Laps the Stock Market: Here's Why - Yahoo Finance
Post-Pfizer dropout, Lilly Achieves GLP-1 win in phase III - BioWorld MedTech
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Yahoo Finance
Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
GSK Zantac Appeal Gets Tough Questions From Some US Judges - Bloomberg.com
U.S. Unfractionated Heparin Market Is Booming Worldwide 2025-2032 | Pfizer, Inc., Sagent Pharmaceuticals - openPR.com
Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention - Yahoo Finance
BMO Capital Adjusts Price Target on Pfizer to $30 From $36 - marketscreener.com
Neuroendocrine Tumor Treatment Market Is Booming Worldwide | - openPR.com
Viking Therapeutics (VKTX) Shares Surge on Pfizer's Decision - GuruFocus
Pfizer, GSK to gain as CDC ACIP votes for RSV shots (NYSE:PFE) - Seeking Alpha
It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope - simplywall.st
Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha
Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq
Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - marketscreener.com
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire
Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha
1.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):